I’m a medical device guy. I know enough about pharmaceuticals to be dangerous. Actually, I know very little. My knowledge and understanding of the pharma industry increased exponentially today during the Indiana Life Sciences Forum. One of the panels was focused on Big Pharma:
Panel: Big Pharma – What are the Big Pharmas going to look like and what does that mean for the rest of us?
- Sidney Taurel, Chairman Emeritus, Eli Lilly and Company (Confirmed)
- William Ringo, SVP, Strategy and Business Development, Pfizer (Confirmed)
- Jas Gidda, VP of Research and Development, Marcadia Biotech (Confirmed)
- Matthew K. Hudes, National Managing Principal, Biotechnology, Life Sciences & Health Care, Deloitte LLP (Confirmed)
- Moderated by: Â G. Steven Burrill, CEO, Burrill & Company (Confirmed)
The closing comments from each panelist addressed the top issues big pharma needs to face in the next 10 years. Here are some of the responses:
Ringo
- Change public perception of the pharmaceutical industry. Public perceives 60% of healthcare costs comes from pharma. In reality, it’s closer to 12%.
- Improve productivity of research & development.
- Figure out how to capitalize in emerging markets with established products.
Taurel
- Improve the worldwide climate for innovation
- Address market-based demands instead of cost-based demands
- Establish regulatory standards / approaches for personalized medicine.
- Adapt approach for patient outcomes.
- Change internal thinking at big pharma companies from “ways to generate most revenue” to “what is best for the patient”.
Gidda
- Focus on patient first.
- Research & development.
- Change public perception.
Hudes
- Reform healthcare.
- Increase mergers & acquisitions. Increase R&D.
- Advancement of biosimilars and generics.
- Increase spending and development in healthcare IT. $31B allocated by federal government that could be tapped by life science R&D.
Burrill
- Change viewpoint from U.S. centric to more of a world view. Rest of world operates on single-payer system (governments).
- Foster and finance innovation.
The panel was a group of heavy hitters in pharma. What I found most interesting about the discussion:
- A great deal of the discussion was about lowering costs. None mentioned value explicitly.
- Why hasn’t pharma ALWAYS had a patient first focus?
![Reblog this post [with Zemanta]](http://img.zemanta.com/reblog_e.png?x-id=f6a89122-2792-4e3b-883f-22e1aa8d7876)